- Spontaneous Model(s) TgA86 mice
- Readouts In vivo scoring, Histopathology
Ankylosing Spondylitis (SpA) is a bone pathology that belongs to a superfamily of spondyloarthritides. SpA involves both axial and peripheral arthritis-like pathology characterized by inflammation and structural damage accompanied by new bone formation that may gradually lead to joint ankylosis. In AS the primary site of inflammation is located at the enthesis or subchondral bone marrow with bone marrow oedema, infiltration of inflammatory cells and increased osteoclast density.
Our Preclinical Testing Tools
Biomedcode has recently added in its collection of unique animal models of human disease the TgA86 mouse model spontaneously developing ankylosing spondylitis due to the overexpression of mouse transmembrane TNF.
Ankylosing Spondylitis Evaluation Platforms
Mice can be treated either early -at disease onset- or late –at established pathology. Disease progress and severity are assessed regularly using validated in vivo scoring scales for peripheral and axial pathology.
In vivo peripheral pathology scoring
In vivo axial pathology scoring
Histopathological evaluation of joint sections
Histopathological evaluation of tail vertebrae sections
Mouse tmTNF driven spondyloarthritis (TgA86)
TgA86 mice overexpress mouse transmembrane TNF from a Δ1-12 mTNF-globin transgene and develop chronic inflammatory arthritis and axial spondylitis pathology from the first weeks of age. Disease is clinically manifested as peripheral arthritis accompanied by a hunchback formation and crinkled tails.
Representative graphs of the progression of the in vivo arthritic score (left panel) and the tail pathology score (right panel) in TgA86 animals. Treatment with etanercept ameliorates the disease symptoms.